1.1 Multi-Organ-Chips I Monday, 21 September 2015 09:00-10:30
|
|
|
Six organ chip for substance toxicity testing using Homunculus platform Dmitry Sakharov, RU-Moscow |
|
|
Pro-drug activation in a dynamic microfluidic systems interconnecting liver and tumor micro-tissues" Jens Kelm, CH-Schlieren |
|
|
Mimicking the cyclic mechanical stress of the lung parenchyma in a breathing lung-on-chip Janick Stucki, CH-Bern |
1.2 Multi-Organ-Chips II Monday, 21 September 2015 15:30-17:00
|
|
|
Microfluidic in vitro platform for parallel human multi-tissue interaction studies Jin-Young Kim, CH-Zurich |
|
|
Emulating the human vasculature in a multi-organ-chip platform Tobias Hasenberg, DE-Berlin |
|
|
Cryopreserved human hepatocytes and IdMOC experimental system for the evaluation of human drug properties Albert Li, US-Columbia MD
|
2 Stem Cells Monday, 21 September 2015 09:00-10:30
|
|
|
Geometrically confined cell differentiation and migration model for human teratogen detection Jiangwa Xing, SG-Singapore |
|
|
Quantitative data on toxicant classification derived from transcriptomics studies of stem cell development Marcel Leist, DE-Konstanz |
|
|
Vascular-like network enhances structural and functional maturation of human pluripotent stem sell derived cardiomyocytes in cardiovascular construct Hanna Vuorenpää, FI-Tampere |
|
|
Human induced pluripotent stem cells as tools for studying the etiology of Non Alcoholic Fatty Liver Disease James Adjaye, DE-Düsseldorf |
|
|
Differentiated human skin-derived stem cells as a novel cell source for in vitro screening of drug-induced liver injury (DILI) Vera Rogiers, BE-Brussels |
3.1 3D Models I Sunday, 20 September 2015 16:00-17:30
|
|
|
Comparative human and rat neurospheres reveal species differences in chemical effects on neurodevelopmental key events Ellen Fritsche, DE-Düsseldorf |
|
|
Stem-cell based in vitro models to study human CNS pathophysiology Zeynab Nayernia, CH-Geneva |
|
|
The use of the 'Neurosphere-Assay’ to study specific disturbances on FGF-2 function during neurodevelopment Marta Barenys, DE-Düsseldorf |
|
|
Assessment of the predictivity of neuronal networks coped to microelectrode arrays for identification of neurotoxicants Tzutzuy Ramirez, DE-Ludwigshafen |
|
|
Advances in in vitro testing: the route to replace animal testing Stella Homer, UK-Rotherham |
3.2 3D Models II Tuesday, 22 September 2015 13:30-15:00
|
|
|
The HuALN model for testing immune reactivity in vitro Christoph Giese, DE-Berlin |
|
|
Optimization of an eye irritation assay for hazard identification and labelling of materials to address the EU Cosmetic Directive and REACH Legislation Yulia Kaluzhny, US-Ashland MA |
|
|
Versatile, polymer-based devices for multi-parameter in vitro toxicology Roisin Owens, FR-Gardanne |
|
|
A microfluidics integrated electronic monitoring system of a 3D in vitro model of the renal tubule Vincenzo Curto, FR-Gardanne |
|
|
Omnisphero: A novel computational approach for high content image analyses (HCA) of organoid neurosphere cultures in vitro Martin Roland Schmuck, DE-Düsseldorf |
4 International Progress in 3Rs' research & Global Cooperation on Implementing the 3Rs Monday, 21 September 2015 13:30-15:00
|
|
|
Beyond Europe: Accelerating regulatory uptake and use of 3R best practices globally Troy Seidle, CA-Toronto |
|
|
EPAA - 10 years of progress and more to do Renate Weissenhorn, BE-Brussels |
|
|
The Asian Congress on Alternatives and Animal Use in the Life Sciences 2016 Hajime Kojima, JP-Tokyo |
|
|
Transatlantic collaboration of Cosmetics Europe with NICEATM/ILS to assess and develop strategy for skin sensitisation safety assessment without animal testing Sebastian Hoffmann, DE-Paderborn |
|
|
Decision Algorithm for 3R (Refine, Reduce, Replace) Programs - a case study in vaccines Iwona Wilk-Zasadna, CH-Basel |
paid advertising
|
5.1 QSAR & Read Across I - Read Across Tuesday, 22 September 2015 13:30-15:00
|
|
|
Preventing unnecessary testing by means of read-across: scope, justification and assessment Karel de Raat, FI-Helsinki |
|
|
New tools to assist in the application of the read-across approach Alessandra Roncaglioni, IT-Milano |
|
|
VPA Read across: Development of predictive biomarkers by using toxicity data of structurally similar compounds Regina Stöber, DE-Hannover |
|
|
Metabolomics as a read across tool Tzutzuy Ramirez, DE-Ludwigshafen |
5.2 QSAR & Read Across II - QSAR Monday, 21 September 2015 11:00-12:30
|
|
|
Use of (Q)SARs under REACH - perspective of a regulator Matthias Herzler, DE-Berlin |
|
|
Application of in silico methods for predictions of different toxicological endpoints Malgorzata Drwal, DE-Berlin |
|
|
QsarDB: solution strategy for efficient use of QSAR models Uko Maran, EE-Tartu |
|
|
The Future of the QSAR Toolbox: moving to less uncertainty in predictive toxicology Romualdo Benigni, IT-Roma |
|
|
Weighted gene co-expression network analysis to characterize drug induced cardiotoxicity Jufeng Wang, CN-Beijing |
6 Risk assessment based on the AOP concept Monday, 21 September 2015 13:30-15:00
|
|
|
MIEs – the gateways to pathway prediction Paul Russell, UK-Shambrook |
|
|
Integration of the epidemiological data with the experimental toxicity studies on pesticides; use of the AOP framework for the definition of biological plausibility Andrea Terron, IT-Parma |
|
|
Characterization of the effects of epigallocatechin gallate (EGCG) exposure during neurodevelopment within the AOP concept Marta Barenys, DE-Düsseldorf |
|
|
Applying Adverse Outcome Pathways to support Integrated Approaches to Testing and Assessment (IATA) João Barroso, IT-Ispra |
|
|
Adverse Outcome Pathway Knowledge Base: A crowdsourcing tool to add value to existing information on Alternative Methods results Clemens Wittwehr, IT-Ispra |
7 Repeated Dose Toxicity & Other Toxicological Endpoints Tuesday, 22 September 2015 11:00-12:30
|
|
|
Towards the replacement of in vivo repeated dose systemic toxicity: Achievements of the SEURAT-1 research initiative Tilmann Gocht, DE-Tübingen |
|
|
Metabolomics in vitro: a new approach for systemic toxicity – first applications for mode of action identification and chemical grouping Tzutzuy Ramirez, DE-Ludwigshafen |
|
|
28-day microphysiological monitoring of human hepatocellular cells Joachim Wiest, DE-Munich |
|
|
Generation of the molecular basis for studying thyroid hormone disruption in neural progenitor cells of humans and rats Susanne Giersiefer, DE-Düsseldorf |
|
|
Quantitative analysis of cell migration in the wound healing scratched assay by Using Active Contour Model and Speeded Up Robust Features Melika Farshad, IR-Shiraz |
|
|
Failure and Success: in vitro ocular irritation test methods for agrochemical formulations the Bovine Cornea Opacity and Permeability Test and the EpiOcular™ Eye Irritation Test Susanne Kolle, DE-Ludwigshafen |
8 Inhalation Tuesday, 22 September 2015 13:30-15:00
|
|
|
Cellular human based systems for investigating the toxicity effects of inhalable substances Samuel Constant, CH-Geneva
|
|
|
Systems Toxicology-based assessment of aerosols using human organotypic tissue cultures of nasal and bronchial epithelium Julia Hoeng, CH-Lausanne |
|
|
Characterization of 3D reconstructed human airway models used for biomarker and inflammatory response studies Rodger Curren, US-Gaithersburg MD |
|
|
Preliminary validation studies of a 3D in vitro inhalation model, using cytokine and gene expression responses to metal-oxide particles Ingeborg Kooter, NL-Utrecht |
|
|
Building a framework of communication between industry and regulators to identify in vitro methods suitable for tobacco regulatory science Erin Hill, US-Gaithersburg MD |
9.1 Skin Sensitization I Sunday, 20 September 2015 13:45-15:15
|
|
|
Outlook on currently available non-animal test methods for skin sensitization testing Daniel Urbisch, DE-Ludwigshafen |
|
|
Reconstituted Human Epidermis Models and IL-18 Levels for Identification and Potency Ranking of Skin Sensitizers: Identification of Critical Steps and Harmonization of Existing Protocols for the Purpose of Validation Erwin Roggen, DK-Bagsvaerd |
|
|
Evaluating non-animal methods for identifying skin sensitisation hazards: A Bayesian value of information analysis Maria Leontaridou, DE-Ludwigshafen |
9.2 Skin Sensitization II Tuesday, 22 September 2015 11:00-12:30
|
|
|
Towards the assessment of skin sensitization potency: Quantitative estimations by the Direct Peptide Reactivity Assay Susanne Kolle, DE-Ludwigshafen |
|
|
From pathways to people: Applying the skin sensitisation AOP to risk assessment Gavin Maxwell, UK-Shambrook |
|
|
Functional characterization of reconstructed skin containing in vitro generated Langerhans cells Günther Weindl, DE-Berlin |
|
|
Evaluation of an in vitro human dermal sensitization test for use with medical device extracts Jamin A. Sr. Willoughby, US-Kalamazoo MI |
10.1 Efficacy & Safety Testing I Tuesday 22 September 2015 09:00-10:30
|
|
|
A relevant in vitro model for safety testing of chemicals and efficacy testing of pharmaceuticals Tuula Heinonen, FI-Tampere |
|
|
Characterization of transporter activities in different cell types by using fluorescent substrates Anett Ullrich, DE-Schwerin |
|
|
Development, optimization and standardization of an in vitro skin irritation test for medical devices using the reconstructed human tissue model EpiDerm Helena Kandarova, SK-Bratislava |
|
|
HTS for screening of selective muscarinic cholinergic receptors antagonists Valerii Tonkopii, RU-St. Petersburg
|
10.2 Efficacy & Safety Testing II - Biological and Vaccines Monday, 21 September 2015 09:00-10:30
|
|
|
In vitro assays for the potency determination of botulinum neurotoxin serotypes A and B Emina Wild, DE-Langen |
|
|
Avian encephalomyelitis live vaccines - alternative methods for batch virus titration Lena Rimpel, DE-Langen |
|
|
Pro- and pre-hapten mechanisms in skin sensitization David Roberts, UK-Liverpool |
|
|
LLNA variability: an essential ingredient for a comprehensive assessment of non-animal skin sensitisation test methods and strategies Sebastian Hoffmann, DE-Paderborn |
11 Nano-Toxicology Monday, 21 September 2015 11:00-12:30
|
|
|
Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long term opportunities? Natalie Burden, UK-London |
|
|
NanoSafety research and its challenges! Peter Wick, CH-St. Gallen |
|
|
Cytotoxic and immunological effects of engineered nanomaterials Marika Mannerstrom, FI-Tampere |
|
|
Adressing inflammatory parameters of the intestinal mucosa: From the mouse to the test tube Benno Weigmann, DE-Erlangen |
|
|
An advanced 3D human epithelial airway model to study the biokinetics of aerosolized biomedical nanoparticles after repeated exposures Savvina Chortarea, CH-Fribourg |
|
|
Towards the prediction of nanoparticle-induced inhalation toxicity: Evaluation of an in vitro macrophage assay Martin Wiemann, DE-Münster |
|
|
A decision-making framework for the grouping and testing of nanomaterials
|
paid advertising
|
12.1 Disease Models I: CRISPR/Cas Sunday, 20 September 2015 16:00-17:30
|
|
|
Scientific and animal welfare issues surrounding the new CRISPR/Cas-9 approach to produce transgenic animals and advanced in vitro disease models Horst Spielmann, DE-Berlin |
|
|
CRISPR/Cas-induced structural variants Malte Spielmann, DE-Berlin |
|
|
Paving the way to a novel analysis platform to study human diseases Saniye Sprenger, DE-Berlin |
|
|
Modeling the air-blood-barrier in state of disease – challenges and perspectives Marius Hittinger, DE-Saarbrücken |
12.2 Disease Models II: hiPSC Monday, 21 September 2015 11:00-12:30
|
|
|
Reconstructed human skin pioneers the implementation of diversity into preclinical testing in vitro Monika Schäfer-Korting, DE-Berlin |
|
|
Human stem-cell based functional neuronal in vitro disease models Susanna Narkilahti, FI-Tampere |
|
|
Alzheimer's disease research in the 21st century: the shift towards a new paradigm Francesca Pistollato, US-Washington DC |
|
|
In vitro hiPSC-based modeling of late-onset disease using progerin-induced aging Justine Miller, US-Rensselaer NY |
12.3 Disease Models III: Inflammation Wednesday, 23 September 2015 09:00-10:30
|
|
|
Modular human biochip-based organoid models in sepsis research Alexander Mosig, DE-Jena |
|
|
Use of ex vivo organotypic lung tissue in translational research of respiratory injury and inflammation diseases Katherina Sewald, DE-Hannover |
|
|
Evaluation of selumetinib and trametinib MEK inhibitors antitumor efficacy in a preclinical in vitro human lung cancer model Samuel Constant, CH-Geneva |
|
|
Phenotypic responses of human asthmatic airway epithelial cultures to rhinovirus and poly(I:C) Patric Hayden, US-Ashland MA |
|
|
Small Airway-on-a-Chip: A novel human inflammatory disease model Kambez Benam, US-Boston MA |
13 Biobarriers Wednesday, 23 September 2015 11:00-12:30
|
|
|
Biophysical and metabolic properties of striae distensae evaluated ex vivo compared to normal skin Youna Coquin, FR-Saint Gregoire |
|
|
Assess the bio-barrier function of the human respiratory system using an in vitro 3D model of airway epithelial model (MucilAir™) Samuel Constant, CH-Geneva |
|
|
Intelligent inserts as scaffolds for functional cell co-culture models on a biomimetic scale Silvia Angeloni, CH-Neuchâtel |
|
|
In vitro models of skin wounds – potential, limitations and perspectives Maike Windbergs, DE-Saarbrücken |
|
|
Epithelial-endothelal co-cultures to mimic the air-blood-barrier Brunhilde Blömeke, DE-Trier |
|
|
What happens when the particle has landed? – In vitro models for studying post-deposition events of aerosolized particles Marius Hittinger, DE-Saarbrücken |
14 EU Directive 2010/63/EU on the Protection of Animals Used for Scientific Purposes Monday, 21 September 2015 13:30-15:00
|
|
|
Directive 2010/63/EU: five years after its adoption Herman Koeter, NL-Den Haag |
|
|
Non-technical summaries - a review of EU member states efforts so far Katy Taylor, UK-London |
|
|
Different concepts of committees in EU member states, to support the competent authorities performing the project evaluation according to Directive 2010/63/EU Norbert Alzmann, AT-Vienna |
|
|
The Role of the National Committee in Germany - Severity Assessment of Genetically Altered Animals Bettina Bert, DE-Berlin |
|
|
Legal issues in the work of the German National Committee: an overview Justyna Chmielewska, DE-Berlin |
15.1 Ethics & Legal Issues I Monday, 21 September 2015 15:30-17:00
|
|
|
Pain for Profit. Can monetary reasons justify animal research ethically? Herwig Grimm, AT-Vienna |
|
|
Evaluation of the scientific validity of animal experiments in Switzerland Lucile Vogt, CH-Bern |
|
|
Implementing the 3Rs: turning words into action Emily McIvor, UK-Seaton |
15.2 Ethics & Legal Issues II Tuesday, 22 September 2015 09:00-10:30
|
|
|
Update on 3Rs activities at the EU institutional level and beyond the borders Francois Busquet, BE-Brussels |
|
|
40 years of Animalfree Research. Results and lessons learned from a quality assessment Stefanie Schindler, CH-Zurich |
|
|
Non-animal Testing: It’s within REACH Julia Baines (replacing Gilly Stoddart), UK-Colchester |
|
|
REACH, the Cosmetics Regulation and upholding the animal testing ban Julia Baines, UK-Colchester |
|
|
Harm-benefit analysis of animal experimentation: a qualitative study of ethics committee practice in six European countries Anna Olsson, PT-Porto |
16.1 Refinement I and Culture of Care Tuesday, 22 September 2015 15:30-17:00
|
|
|
Working together to develop and implement a 'culture of care' Kirsty Reid, BE-Brussels |
|
|
Pain Management and post-operative monitoring and care of laboratory rodents in Germany – lessons learnt and recommendations to improve practice Kathrin Herrmann, DE-Berlin |
|
|
Ending severe suffering: the scientific animal welfare organization as a catalyst for change Elliot Lilley, UK-Horsham |
|
|
Refinement facilitated by the Culture of Care Susanna Louhimies, BE-Brussels |
16.2 Refinement II Tuesday, 22 September 2015 11:00-12:30
|
|
|
Barriers to the implementation of refinements in animal laboratories Katy Taylor, UK-London |
|
|
Refinement strategies in experimental autoimmune encephalomyelitis (EAE) in mice Kristina Ullmann, DE-Berlin |
|
|
Community guidelines on animal studies - ALS research as a case-study Nuno Henrique Franco, PT-Porto |
|
|
The role of the animal welfare officer on the 3R´s principle in laboratory animal science in Germany Christa Thöne-Reineke, DE-Berlin |
|
|
Ethics review of animal experiments in Europe under Directive 2010/63/EU Anna Olsson, PT-Porto |
17.1 Replacement I Tuesday, 22 September 2015 09:00-10:30
|
|
|
Animals are not 'Materials and Methods': Why it is important to focus on Replacement Candida Nastrucci, IT-Rome |
|
|
Examination of human bone tissue regeneration using the chorioallantoic membrane (CAM): an ex vivo replacement model for animal research Ines Moreno, UK-Southampton |
|
|
Strategies for combining skin and vasculature in a Multi-Organ-Chip Platform Katharina Schimek, DE-Berlin |
|
|
Stem cell-derived human dorsal root ganglia-like cells to identify peripheral neurotoxicants Lisa Hoelting, DE-Konstanz |
|
|
Functional neurons from cancer cells: a novel in vitro model exhibits appropriate functional parameters Susanna Alloisio, IT-Genoa |
17.2 Replacement II Tuesday, 22 September 2015 15:30-17:00
|
|
|
3D biocompatibility test systems mimicking the in vivo situation: evaluation of a hydroxyapatite-nanoparticular paste Veronika Hruschka, AT-Vienna |
|
|
A mismatch between micro-motives and macro-behaviour: The inefficiency of efforts toward replacement at the individual level Jan Lauwereyns, JP-Fukuoka |
|
|
New guidance on information requirements for skin corrosion/irritation and serious eye damage/eye irritation under REACH Bohumila Bichlmaier Suchanová, FI-Helsinki |
|
|
Replacement – coming closer to a dream Thomas Hartung, US-Baltimore MD |
18.1 3Rs in Academia & Education I Sunday, 20 September 2015 13:45-15:15
|
|
|
The Berlin-Brandenburg Research Platform BB3R and integrated graduate school Monika Schäfer-Korting, DE-Berlin |
|
|
CERST-NRW: a German state government of North Rhine Westphalia-funded initiative for the development of alternative methods to animal testing Ellen Fritsche, DE-Düsseldorf |
|
|
Teaching alternative methods in toxicology in veterinary science Francesca Caloni, IT-Milano |
|
|
Romanian Center for Alternative Test Methods (ROCAM) – a newly established 3Rs Center to promote and support the alternative methods field in Romania Lucian Farcal, RO-Cluj-Napoca |
|
|
CAAT-Europe and knowledge exchange on the progress of the 3Rs and research methods Marcel Leist, DE-Konstanz |
18.2 3Rs in Academia & Education II Monday, 21 September 2015 15:30-17:00
|
|
|
Reboot3R - Design Thinking Workshops for scientists to constructively find ways to apply 3Rs within their own career Cecilia Hilmer, DE-Berlin |
|
|
Animal Research: critical, challenging & creative thinking about the 3Rs Juliet Dukes, UK-Southwater |
|
|
A Course in Alternatives: focus on replacement and non-animal methods Candida Nastrucci, IT-Rome |
|
|
Follow-up on 2013 EUSAAT’s Congress and its impact for Sri Lankan scientific community in 3Rs Mangala Gunatilake, LK-Colombo |
|
|
Improving animal welfare through competence: The EUPRIM-Net education and training programs Valeska Marija Stephan, DE-Göttingen |
|
|
Refinement of welfare through application of a quantitative system for assessment of lifetime experience Michael Dennis, UK-Salisbury |
|
|
Journal policies on animal use – current landscape and future directions Nuno Henrique Franco, PT-Porto |
19.1 Young Scientists Short Lectures I Tuesday, 22 September 2015 15:30-17:00
|
|
|
A 3D in vitro iPSC derived mini-brain model to study Parkinson’s disease David Pamies, US-Baltimore MD |
|
|
Molecular modelling of osteoarthritis – evaluating pathways in vitro Annemarie Lang, DE-Berlin |
|
|
A novel human organotypic tumor invasion model of cell line MDA-MB-231 in Precision-Cut Lung Slices (PCLS) to reduce animal experiments in preclinical oncology Sebastian Konzok, DE-Hannover |
|
|
Impaired skin barrier function of cutaneous squamous cell carcinoma Christopher Wolff, DE-Berlin |
|
|
Generation of 3D neurospheres from human induced pluripotent stem cells as an alternative in vitro method to study neurodevelopmental defects of Cockayne Syndrome patient Maxi Hofrichter, DE-Düsseldorf |
|
|
Human lymphoblastoid cell lines as an in vitro tool in preclinical drug evaluation Tijana Markovic, SI-Ljubljana |
|
|
Systematic assessment of different computational approaches for prediction of toxic effects of new chemical structures Priyanka Banerjee, DE-Berlin |
19.2 Young Scientists Short Lectures II Wednesday, 23 September 2015 11:00-12:30
|
|
|
Chip-based co-culture of neurospheres and liver spheroids for long-term substance testing Anja Ramme, DE-Spreenhagen |
|
|
Human in vitro Blood-Brain Barrier model generated from stem cells: reducing attrition in the Central Nervous System area Aurore Drolez, FR-Lens |
|
|
A microfluidic four-organ-chip – a potential tool for ADME profiling Juliane Hübner, DE-Berlin |
|
|
In vitro investigation on uptake, cytotoxicity and genotoxicity of two similar sized titanium oxide nanoparticles on the human hepatic cells HepaRG Pegah Jalili, FR-Fougeres |
|
|
Optimization of a new in vitro method for inhalation toxicology and its application for the study of zinc oxide nanoparticle toxicity Emilie Da Silva, DK-København |
|
|
Assessment of sensitization and photosensitization of benzophenone-3 based on DPRA Carolina Benevenuto, BR-Brazil |